Baldwin Applauds First 10 Drugs Announced for Medicare Price Negotiation Under Inflation Reduction Act
9 Million Americans spent more than $3.4 billion on these 10 drugs to treat life-threatening conditions like diabetes, heart disease and cancer
WASHINGTON, D.C. – Today, Senator Tammy Baldwin (D-WI) is applauding the first 10 drugs selected for Medicare price negotiation under the Baldwin-backed Inflation Reduction Act. The law, which allows Medicare to negotiate the price of dozens of drugs with manufacturers for the first time ever, will cut out-of-pocket costs for seniors, save American taxpayers billions of dollars, and reduce the deficit. In 2022 alone, approximately 9 million seniors and other Medicare beneficiaries spent over $3.4 billion out-of-pocket on the 10 drugs selected for negotiation. Millions of Part D enrollees depend on these vital drugs to treat life-threatening conditions including diabetes, heart failure, and cancer, but many struggle to access their medications because of prohibitive costs.
“No Wisconsinite should go broke just to afford the medications they need to stay healthy. Our Inflation Reduction Act finally took on big drug companies and is lowering drug prices, reducing out-of-pocket costs for families and saving taxpayers billions of dollars,” said Senator Baldwin. “I am so proud that our work is lowering drug prices and providing support for tens of thousands of Wisconsinites who rely on these drugs to treat heart disease, diabetes and cancer.”
Negotiations for the first group of selected drugs will begin in 2023, with negotiated prices going into effect in 2026. The number of drugs subject to price negotiation will increase over time. According to the Congressional Budget Office, this provision from the Inflation Reduction Act is estimated to lower average drug prices in Medicare and will reduce the budget deficit by $25 billion in 2031.
This historic provision in the Inflation Reduction Act is just one way the legislation is lowering health care costs for Wisconsinites. The Baldwin-backed law is also capping the cost of insulin for seniors at $35 per month, making no-cost vaccines available to Wisconsinites on Medicare, and penalizing drug companies that raise prices faster than inflation.
An online version of this release is available here.
NOTE: This press release was submitted to Urban Milwaukee and was not written by an Urban Milwaukee writer. While it is believed to be reliable, Urban Milwaukee does not guarantee its accuracy or completeness.
Mentioned in This Press Release
Recent Press Releases by U.S. Sen. Tammy Baldwin
Baldwin Presses Ascension on Decision to Outsource Staffing of Intensive Care Units to Private Equity-Backed Firm
Aug 15th, 2025 by U.S. Sen. Tammy BaldwinTeamHealth, a private equity-backed firm, has history of business practices that compromise patient care and safety
Baldwin, Moore, Steil Call for Trump Administration to Provide Immediate Federal Support for Flood Damage in Southeastern Wisconsin
Aug 14th, 2025 by U.S. Sen. Tammy BaldwinLawmakers support Wisconsin’s request for assistance with federal damage assessment
Report Shows Affordable Care Act Plans Will Cost Up to 34% More in Wisconsin in 2026 Without Congressional Action
Aug 12th, 2025 by U.S. Sen. Tammy BaldwinIncrease is in large part due to Republicans’ refusal to extend key tax break that Baldwin has long championed